ViraCyte gets IP from Baylor; deal expanded to address coronavirus pandemic
Baylor College of Medicine licensed ViraCyte LLC exclusive global rights (including rights to sublicense) to intellectual property associated with virus-specific T-cell immunotherapies aimed at preventing and/or treating viral infections.
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.